Pfizer Limited
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vi… Read more
Pfizer Limited (PFIZER) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.156x
Based on the latest financial reports, Pfizer Limited (PFIZER) has a cash flow conversion efficiency ratio of 0.156x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹5.99 Billion) by net assets (₹38.48 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pfizer Limited - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Pfizer Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pfizer Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pfizer Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The RealReal Inc
F:6RR
|
-0.050x |
|
Pan Jit International Inc
TW:2481
|
-0.010x |
|
Chengdu ALD Aviation Manufacturing Corp
SHE:300696
|
-0.006x |
|
Banque Cantonale de Geneve
SW:BCGE
|
0.082x |
|
Hubei Tech Semiconductors Co
SHE:300046
|
0.008x |
|
Shanghai Feilo Acoustics Co Ltd
SHG:600651
|
0.054x |
|
Viglacera Corp JSC
VN:VGC
|
0.209x |
|
Lovisa Holdings Ltd
AU:LOV
|
1.157x |
Annual Cash Flow Conversion Efficiency for Pfizer Limited (2005–2025)
The table below shows the annual cash flow conversion efficiency of Pfizer Limited from 2005 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹42.17 Billion | ₹6.60 Billion | 0.156x | +119.00% |
| 2024-03-31 | ₹35.96 Billion | ₹2.57 Billion | 0.071x | -35.59% |
| 2023-03-31 | ₹32.07 Billion | ₹3.56 Billion | 0.111x | -52.38% |
| 2022-03-31 | ₹28.64 Billion | ₹6.67 Billion | 0.233x | +30.42% |
| 2021-03-31 | ₹23.93 Billion | ₹4.27 Billion | 0.179x | +87.62% |
| 2020-03-31 | ₹33.95 Billion | ₹3.23 Billion | 0.095x | +193.03% |
| 2019-03-31 | ₹30.11 Billion | ₹978.10 Million | 0.032x | -73.73% |
| 2018-03-31 | ₹26.83 Billion | ₹3.32 Billion | 0.124x | -9.03% |
| 2017-03-31 | ₹24.19 Billion | ₹3.29 Billion | 0.136x | -16.22% |
| 2016-03-31 | ₹21.18 Billion | ₹3.44 Billion | 0.162x | +182.10% |
| 2015-03-31 | ₹19.73 Billion | ₹1.13 Billion | 0.058x | -71.41% |
| 2014-03-31 | ₹6.58 Billion | ₹1.32 Billion | 0.201x | +4060.27% |
| 2013-03-31 | ₹16.94 Billion | ₹-86.07 Million | -0.005x | -127.10% |
| 2012-03-31 | ₹13.05 Billion | ₹244.59 Million | 0.019x | -86.64% |
| 2011-03-31 | ₹11.63 Billion | ₹1.63 Billion | 0.140x | +86.88% |
| 2010-03-31 | ₹9.94 Billion | ₹746.73 Million | 0.075x | -71.54% |
| 2009-03-31 | ₹9.01 Billion | ₹2.38 Billion | 0.264x | +941.98% |
| 2008-03-31 | ₹6.50 Billion | ₹164.53 Million | 0.025x | -90.96% |
| 2007-03-31 | ₹4.40 Billion | ₹1.23 Billion | 0.280x | +2.51% |
| 2006-03-31 | ₹3.76 Billion | ₹1.03 Billion | 0.273x | +6.40% |
| 2005-03-31 | ₹3.40 Billion | ₹872.08 Million | 0.257x | -- |